Skip to main content

Lung cancer


03-07-2020 | COVID-19 | News

Potential for anticancer, COVID-19 drug interactions highlighted

A French team has drawn attention to the potential for drug–drug interactions between anticancer medications and agents being used or tested for the treatment of COVID-19.

02-07-2020 | Non-small-cell lung cancer | News

Support for ‘plasma-first’ approach in molecular testing for NSCLC

Comprehensive circulating tumor DNA analysis can identify therapeutically targetable driver and resistance mutations in patients with advanced non-small-cell lung cancer, research indicates.

29-06-2020 | EMA | News

Entrectinib receives positive decision from EMA

More details about the announcement are a click away

26-06-2020 | Small-cell lung cancer | News

First-line stereotactic radiosurgery an option for brain metastases in SCLC

Patients with small-cell lung cancer and brain metastases may benefit from first-line treatment with stereotactic radiosurgery, suggest findings from the FIRE-SCLC study.

26-06-2020 | Lung cancer | News

Lung cancer patient-specific factors ‘greatest determinants’ of COVID-19 severity

The burden of severe COVID-19 tends to be high in people with lung cancer, with patient-specific factors having the greatest impact on severity, indicates a chart review from a single center.

25-06-2020 | TRK inhibitors | News

On-target TRK inhibitor safety profile highlighted

TRK inhibitor therapy has a “unique” profile of adverse events, suggests a review of lung cancer and other oncology patients attending the Memorial Sloan Kettering Cancer Center in New York, USA.

23-06-2020 | ASCO 2020 | Conference coverage | News

First-line pembrolizumab–chemotherapy prolongs PFS in extensive-stage SCLC

Patients with extensive-stage small-cell lung cancer derive a progression-free survival benefit from first-line treatment with pembrolizumab plus chemotherapy, show phase 3 KEYNOTE-604 trial findings.

22-06-2020 | Non-small-cell lung cancer | News

Low-dose erlotinib ‘a valid treatment option’ for older, frail NSCLC patients

A phase 2 trial suggests that low-dose erlotinib has clinical activity and a favorable safety profile among older and frail non-small-cell lung cancer patients with EGFR activating mutations.

19-06-2020 | FDA | News

Pembrolizumab approved for advanced TMB-H solid tumors

Read more on this US FDA decision here

18-06-2020 | ASCO 2020 | Conference coverage | News

Ramucirumab–gemcitabine encouraging in second-line malignant pleural mesothelioma

Adding ramucirumab to gemcitabine may significantly improve survival outcomes for patients with malignant pleural mesothelioma who have progressed on first-line platinum–pemetrexed regimens, suggest findings from the phase 2 RAMES study presented at the virtual 2020 ASCO Annual Meeting.

17-06-2020 | FDA | News

Lurbinectedin approved for US metastatic SCLC patients

Click through to read more

15-06-2020 | FDA | News

Brigatinib indication expanded in USA

Click through for more information about this FDA decision

09-06-2020 | ASCO 2020 | News

Pembrolizumab and concurrent chemoradiotherapy show unresectable stage III NSCLC promise

For patients with unresectable stage III non-small-cell lung cancer, first-line pembrolizumab plus concurrent chemoradiotherapy is feasible, say the KEYNOTE-799 investigators.

08-06-2020 | ASCO 2020 | News

VISION: Tepotinib promising for MET exon 14-mutated advanced NSCLC

Individuals with advanced non-small-cell lung cancer positive for MET exon 14 skipping mutations could benefit from treatment with the selective MET inhibitor tepotinib, suggests a phase 2 trial.

05-06-2020 | ASCO 2020 | Conference coverage | News

Concurrent osimertinib–gefitinib feasible in advanced EGFR-mutated NSCLC

Combining osimertinib with gefitinib has promising efficacy and tolerability in treatment-naïve patients with metastatic EGFR-mutated non-small-cell lung cancer, suggest early data presented at the virtual 2020 ASCO Annual Meeting.

02-06-2020 | ASCO 2020 | News

CheckMate 9LA points to first-line nivolumab–ipilimumab plus chemo for advanced NSCLC

CheckMate 9LA findings reported at the virtual 2020 ASCO Annual Meeting support the use of nivolumab plus ipilimumab alongside first-line, histology-driven chemotherapy in advanced non-small-cell lung cancer patients without sensitizing EGFR or ALK mutations.

01-06-2020 | ASCO 2020 | News

Durvalumab–chemotherapy ‘promising’ first-line treatment in mesothelioma

Patients with treatment-naïve and unresectable malignant pleural mesothelioma may respond to treatment with durvalumab given alongside cisplatin and pemetrexed, suggest results from the phase 2 PrE0505 study.

30-05-2020 | ASCO 2020 | News

Adjuvant osimertinib ‘practice changing’ for early-stage EGFR-mutated NSCLC

Patients with stage IB–IIIA non-small-cell lung cancer harboring EGFR mutations derive a significant disease-free survival benefit from adjuvant treatment with osimertinib, shows the phase 3 ADAURA trial.

15-05-2020 | FDA | News

Selpercatinib receives FDA nod

Read more about this approval here

15-05-2020 | Lung cancer | Highlight | News

PD-1 blockade may not adversely affect COVID-19 outcomes

Treatment with PD-1 inhibitors does not appear to worsen the severity of SARS-CoV-2 infection in patients with lung cancer, suggests a single-center analysis.

Image Credits